

Lidia Irene Staszewsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4168267/publications.pdf>

Version: 2024-02-01

75
papers

3,532
citations

186265
28
h-index

138484
58
g-index

77
all docs

77
docs citations

77
times ranked

5264
citing authors

#	ARTICLE	IF	CITATIONS
1	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 727-738.	2.6	2
2	Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort. <i>JACC: CardioOncology</i> , 2022, 4, 98-109.	4.0	29
3	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002708.	2.8	2
4	Semaglutide and effective weight control. <i>Lancet</i> , The, 2021, 397, 942-943.	13.7	6
5	Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. <i>Scientific Reports</i> , 2021, 11, 10635.	3.3	6
6	IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 328.	1.7	9
7	Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats. <i>Medical Gas Research</i> , 2021, 11, 124.	2.3	1
8	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2021, 10, e021071.	3.7	2
9	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 553.	1.7	12
10	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. <i>MethodsX</i> , 2020, 7, 100771.	1.6	1
11	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. <i>Cancers</i> , 2020, 12, 2312.	3.7	5
12	Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs. <i>Journal of the American Heart Association</i> , 2020, 9, e016494.	3.7	15
13	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466.	3.1	16
14	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020, 9, 1418.	2.4	27
15	Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 177-188.	2.5	1
16	Adrenomedullin, a circulating biomarker of congestion: in search of evidence. <i>European Journal of Heart Failure</i> , 2019, 21, 1062-1063.	7.1	2
17	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	7.1	52
18	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. <i>European Journal of Pharmacology</i> , 2019, 865, 172777.	3.5	11

#	ARTICLE	IF	CITATIONS
19	A novel echocardiographic method closely agrees with cardiac magnetic resonance in the assessment of left ventricular function in infarcted mice. <i>Scientific Reports</i> , 2019, 9, 3580.	3.3	15
20	LUCAS Versus Manual Chest Compression During Ambulance Transport: A Hemodynamic Study in a Porcine Model of Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2019, 8, e011189.	3.7	35
21	Effect of mild hypercapnia on outcome and histological injury in a porcine post cardiac arrest model. <i>Resuscitation</i> , 2019, 135, 110-117.	3.0	14
22	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	7.1	93
23	Screening for unknown atrial fibrillation in older people: a feasibility study in community pharmacies. <i>European Geriatric Medicine</i> , 2018, 9, 113-115.	2.8	5
24	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one Atrial. <i>European Journal of Cancer</i> , 2018, 94, 126-137.	2.8	163
25	Duration of Untreated Cardiac Arrest and Clinical Relevance of Animal Experiments: The Relationship Between the No-Flow Duration and the Severity of Post-Cardiac Arrest Syndrome in a Porcine Model. <i>Shock</i> , 2018, 49, 205-212.	2.1	23
26	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 172-179.	2.8	3
27	Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1498-1498.	7.1	1
28	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. <i>Cardiology</i> , 2017, 136, 128-137.	1.4	46
29	Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. <i>European Journal of Heart Failure</i> , 2016, 18, 840-848.	7.1	23
30	Cyclosporine A in Reperfused Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 365-374.	2.8	144
31	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 703-711.	1.5	6
32	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 551-561.	2.6	11
33	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 476-484.	2.8	27
34	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. <i>Cardiovascular Research</i> , 2014, 104, 37-48.	3.8	42
35	Postresuscitation Treatment With Argon Improves Early Neurological Recovery in a Porcine Model of Cardiac Arrest. <i>Shock</i> , 2014, 41, 72-78.	2.1	49
36	Relationship between plasma high-sensitive cardiac Troponin T and infarct size in a porcine model of acute myocardial infarction and cardiac arrest and resuscitation. <i>Resuscitation</i> , 2014, 85, S13-S14.	3.0	0

#	ARTICLE	IF	CITATIONS
37	Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat. <i>Journal of Biomedical Science</i> , 2014, 21, 70.	7.0	18
38	Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute STâ€Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASISâ€6 Trial. <i>Echocardiography</i> , 2014, 31, 569-578.	0.9	22
39	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. <i>Heart Rhythm</i> , 2014, 11, 1641-1647.	0.7	9
40	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 28.	1.7	38
41	Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans. <i>Resuscitation</i> , 2013, 84, 1604-1610.	3.0	35
42	Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. <i>Pharmacological Research</i> , 2013, 73, 35-43.	7.1	22
43	Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013, 166, 935-940.e1.	2.7	35
44	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , 2013, 10, 226-232.	0.7	23
45	What is the atrium trying to tell us?. <i>European Heart Journal</i> , 2013, 34, 255-257.	2.2	11
46	Prevention of Myocardial Remodeling by Chronic INaL Blockade in Pulmonary Hypertension. <i>Biophysical Journal</i> , 2012, 102, 340a.	0.5	0
47	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 131-143.	2.6	10
48	Systematic Review and Meta-Analysis: Renin-Angiotensin System Inhibitors in the Prevention of Atrial Fibrillation Recurrences. An Unfulfilled Hope. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 47-54.	2.6	27
49	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. <i>Cytotherapy</i> , 2011, 13, 1140-1152.	0.7	8
50	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardicoâ€Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2011, 162, 382-389.	2.7	28
51	Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells. <i>PLoS ONE</i> , 2011, 6, e22158.	2.5	21
52	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. <i>Journal of Internal Medicine</i> , 2011, 269, 160-171.	6.0	63
53	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , 2011, 20, 1203-1216.	2.4	8
54	Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation. Circulation: Cardiovascular Imaging, 2011, 4, 721-728.	2.6	14

#	ARTICLE	IF	CITATIONS
55	Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. <i>Blood</i> , 2010, 116, 5130-5139.	1.4	159
56	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. <i>Heart</i> , 2010, 96, 1909-1914.	2.9	31
57	Valsartan for Prevention of Recurrent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 1606-1617.	27.0	442
58	Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. <i>Cardiovascular Research</i> , 2009, 83, 707-716.	3.8	46
59	Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. <i>Cell Death and Differentiation</i> , 2008, 15, 1417-1428.	11.2	94
60	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)â€“3 trial. <i>American Heart Journal</i> , 2008, 155, 388-394.	2.7	26
61	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7284-7291.	7.0	82
62	Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2007, 13, 797-804.	1.7	80
63	Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 70.e23-70.e30.	1.5	95
64	Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 29-38.	1.5	42
65	Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. <i>Current Heart Failure Reports</i> , 2006, 3, 157-163.	3.3	6
66	Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT. <i>European Journal of Heart Failure</i> , 2006, 8, 502-508.	7.1	12
67	Mesoangioblasts, Vessel-Associated Multipotent Stem Cells, Repair the Infarcted Heart by Multiple Cellular Mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 692-697.	2.4	88
68	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2046-2051.	7.1	231
69	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 181-193.	1.8	4
70	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2022-2027.	2.8	206
71	Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. <i>Journal of Cardiac Failure</i> , 2004, 10, 433-441.	1.7	24
72	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 959-968.	1.9	182

#	ARTICLE	IF	CITATIONS
73	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. <i>Journal of the American College of Cardiology</i> , 2002, 40, 970-975.	2.8	228
74	Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in Heart Failure Trial (Val-HeFT). <i>Journal of the American Society of Echocardiography</i> , 2002, 15, 293-307.	2.8	26
75	Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. <i>American Heart Journal</i> , 1999, 138, 247-253.	2.7	136